Mungkan ting hta, prostate cancer gaw, lasha ni hta byin ai, lahkawng ngu na, grau law ai cancer rai nga ai.
Prostate cancer a majaw si ai lam mung grai law ai, 2018 hta mungkan ting hta si ai masha 37,005 daram nga ai.
Raitim, si ai lam gaw ginra langai hte langai grai shai nga ai. Africa sinna gaw mungkan hta prostate cancer a majaw si ai masha grau law ai shara hta manga ngu na shara hta nga nna, Nigeria gaw ndai ginra hta masha grau law ai hte sut masa grau kaba ai shara re.
Nigeria mungdan hta, prostate cancer gaw, la ni hta grau nna byin ai hte si ai lam grau law ai cancer rai nga ai.
Ndai gaw Dingdung America hta si ai htam lahkawng jan re.
Dai ana hpe hpang hkrat ai hte chye lu ai lam, ana jep ai hte chye lu ai lam n law ai lam, ana kap ai lam ni hpe laika hte ka matsing da ai lam hte shiga jaw ai lam n law ai majaw, Nigeria hta si ai masha law wa ai.
USA mungdan hta, la ni hta byin ai cancer ana a majaw si ai lam hta, lawu lahta na prostate cancer ana gaw lahkawng ngu na madung rai nga ai.
1990 ning a shawng daw kaw nna, lawu lahpa nra hta byin ai ana a majaw si ai lam loi loi yawm wa ai raitim, hkamja lam hte seng nna ahkyak ai manghkang langai naw rai nga ai.
Dai majaw, prostate cancer gaw masha si shangun ai ana rai nga ai.
Raitim, dai ana hpe aten dep chye lu nna tsi lajang yang, ana byin ai lam grau kaja wa nna si ai lam yawm wa na re.
Nakata S, Takahashi H, Ohtake N, Takei T, Yamanaka H: Trends and characteristics in prostate cancer mortality in Japan. Int J Urol. 2000, 7 (7): 254-7.
Pishgar F, Ebrahimi H, Saeedi Moghaddam S, Fitzmaurice C, Amini E: Global, Regional and National Burden of Prostate Cancer, 1990 to 2015: Results from the Global Burden of Disease Study 2015. J Urol. 2018, 199 (5): 1224-1232.
Cai Q, Chen Y, Zhang D, Pan J, Xie Z, Xu C, Li S, Zhang X, Gao Y, Hou J, Guo X, Zhou X, Zhang B, Ma F, Zhang W, Lin G, Xin Z, Niu Y, Wang Y: Estimates of over-time trends in incidence and mortality of prostate cancer from 1990 to 2030. Transl Androl Urol. 2020, 9 (2): 196-209.
Feletto E, Bang A, Cole-Clark D, Chalasani V, Rasiah K, Smith DP: An examination of prostate cancer trends in Australia, England, Canada and USA: Is the Australian death rate too high? World J Urol. 2015, 33 (11): 1677-87.
Taksler GB, Keating NL, Cutler DM: Explaining racial differences in prostate cancer mortality. Cancer. 2012, 118 (17): 4280-9.
['N hkap la ai lam: tsi mawan']
['Ndai website gaw hpaji jaw ai hte chye na matu sha galaw da ai.']
['Ndai laika buk hta lawm ai lam ni hpe hkamja lam hte seng nna, ana jep ai (sh) tsi ai lam hta n mai jai lang ai.']
['Ga san ni a mahtai hpe shapraw ya ai neural net gaw, ga shadawn, masha langai ngai hta ana langai ngai mu lu ai lam ni hpe madun ai shaloi, n hkrak ai.']
['Ndai website hta mu lu ai lam ni a majaw, tsi sarawun ni a hpaji jaw ga hpe galoi mung n madat ai sha, hpang hkrat ai lam n galaw u. Tsi hte seng nna, ra kadawn nga ai lam nga yang, 911 hpe shaga u. Ndai website hte dai hpe lang ai lam gaw, tsi sarawun hte machyi masha lapran hku hkau lam n nga ai. BioMedLib hte shi a bungli galaw masha ni, ndai website hta shang lawm ai ni kadai mung, ndai kaw lawm ai shiga hte seng nna, tsun mayu ai lam (sh) tsun ai hku nna, hpa ga sadi jaw ai lam n nga ai.']
['Hti na ahkang n nga ai: copyright']
['1998 ning Digital Millennium Copyright Act, 17 U.S.C. § 512 (the DMCA) gaw Internet kaw mara da ai lam ni gaw US copyright law npu na madu a ahkaw ahkang hpe tawt lai ai ngu kam ai copyright madu ni hpe ahkaw ahkang jaw da ai.']
['Anhte a website hte seng nna, (sh) anhte a magam bungli ni hte seng nna, mara shagun da ai lam ni gaw, na a copyright hpe tawt lai ai ngu nna nang kam ai nga yang, dai lam ni hpe dawm kau na matu (sh) dai ni hpe n mai lu hkra pat kau na matu, nang (sh) na a kasa gaw anhte hpe shana mai ai.']
['Dai shiga ni hpe laika hte ka nna email hte shagun ra ai (email address hpe "Contact" daw kaw mu lu na re).']
['Dai DMCA gaw, na a copyright tawt lai ai lam hpe shana ai hta lawu na lam ni lawm ra ai: (1) tawt lai ai ngu ai copyright lu ai bungli a lam; (2) tawt lai ai ngu ai lam hte seng ai lam hte dai hpe mu tam lu na matu anhte hpe karum ya ai lam; (3) na a matut mahkai lam, na a shara, phone number hte email hte seng ai lam ni; (4) nang mara shagun ai lam gaw copyright madu, shi a agent (sh) tara upadi hte n seng ai ngu ai hpe nang kam ai lam.']
['(5) N teng n man ai sakse hkam ai lam hte seng nna, nang masat da ai hte maren, shana ai lam hta lawm ai shiga ni gaw teng man ai hte, nang tawt lai ai ngu ai copyright hpe hkan sa na ahkang nga ai lam.']
['hte (6) copyright madu a mying hte galaw na ahkang lu ai wa a hkum hkrang (sh) electronic signature.']
['Lahta na lam ni hpe n ka bang ai rai yang, nang shagun ai laika hpe hpang hkrat ai hte n mai htang ai.']
['Matut Mahkai U']
['Gara hku mung san mayu yang email hte shana ya rit.']
How deadly is prostate cancer?
Prostate cancer is the second most common cancer in men worldwide, with an estimated 1.276 million new cases reported in 2018, representing 7.1% of all cancer cases in men.
The mortality rate for prostate cancer is also high, with an estimated 37,005 deaths worldwide in 2018.
However, the mortality rate varies greatly by region, with Western Africa having the fifth-highest risk for prostate cancer mortality in the world, and Nigeria having the largest population and economy in this region.
In Nigeria, prostate cancer is both the most common and most deadly cancer for men, with an estimated 32.8 cases and 16.3 deaths per 100,000 men.
This is more than double the death rate in North America.
Late detection of the disease, limited resources for screening and detection, and decreased documentation and reporting of cases contribute to the high mortality rate in Nigeria.
In the United States, prostate cancer is the second most common cause of cancer death in men, with approximately 40,0000 men dying from the disease each year.
The prostate cancer death rate has been slowly decreasing since the early 1990s, but it remains a significant health concern.
Overall, prostate cancer is a deadly disease, particularly in regions with limited access to medical care and screening resources.
However, early detection and treatment can significantly improve outcomes and reduce mortality rates.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['Hkrang']
['BioMedLib gaw ga san hte mahtai yan hpe shapraw na matu computer (machine-learning algorithms) ni hpe lang ai.']
['Anhte gaw PubMed/Medline kaw na tsi hpaji hte seng ai laika buk wan 35 hte hpang ai. RefinedWeb kaw na mung re.']
